Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts CRDF Hot Sheet
Join SI Premium – FREE
Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.17), $0.04 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $120 thousand versus the consensus estimate of $125 thousand.
For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Scribe Therapeutics files for proposed Nasdaq IPO
- Meta's Zuckerberg Says Ai Agent Tech Progressing Slower Than Expected - Reuters
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
